Browse CBX2

Summary
SymbolCBX2
Namechromobox homolog 2
Aliases MGC10561; Pc class homolog (Drosophila); CDCA6; chromobox homolog 2 (Drosophila Pc class); cell division cyc ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Chromosome Note=Localized in distinct foci on chromatin and in chromocenters. Localizes to the inactive X chromosome. Seems to be recruited to H3K27me3, H3K9ac and H3K3me2 sites on chromatin.
Domain PF17218 CBX family C-terminal motif
PF00385 Chromo (CHRromatin Organisation MOdifier) domain
Function

Component of a Polycomb group (PcG) multiprotein PRC1-like complex, a complex class required to maintain the transcriptionally repressive state of many genes, including Hox genes, throughout development (PubMed:21282530). PcG PRC1 complex acts via chromatin remodeling and modification of histones; it mediates monoubiquitination of histone H2A 'Lys-119', rendering chromatin heritably changed in its expressibility (PubMed:21282530). Binds to histone H3 trimethylated at 'Lys-9' (H3K9me3) or at 'Lys-27' (H3K27me3) (By similarity). Plays a role in the lineage differentiation of the germ layers in embryonic development (By similarity). Involved in sexual development, acting as activator of NR5A1 expression (PubMed:19361780).

> Gene Ontology
 
Biological Process GO:0007548 sex differentiation
GO:0016925 protein sumoylation
GO:0018205 peptidyl-lysine modification
GO:0045137 development of primary sexual characteristics
Molecular Function GO:0003682 chromatin binding
GO:0035064 methylated histone binding
GO:0042393 histone binding
Cellular Component GO:0000151 ubiquitin ligase complex
GO:0000152 nuclear ubiquitin ligase complex
GO:0000785 chromatin
GO:0000791 euchromatin
GO:0000792 heterochromatin
GO:0031519 PcG protein complex
GO:0035102 PRC1 complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-392499: Metabolism of proteins
R-HSA-2559580: Oxidative Stress Induced Senescence
R-HSA-597592: Post-translational protein modification
R-HSA-3108232: SUMO E3 ligases SUMOylate target proteins
R-HSA-2990846: SUMOylation
R-HSA-3108214: SUMOylation of DNA damage response and repair proteins
R-HSA-4570464: SUMOylation of RNA binding proteins
Summary
SymbolCBX2
Namechromobox homolog 2
Aliases MGC10561; Pc class homolog (Drosophila); CDCA6; chromobox homolog 2 (Drosophila Pc class); cell division cyc ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CBX2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCBX2
Namechromobox homolog 2
Aliases MGC10561; Pc class homolog (Drosophila); CDCA6; chromobox homolog 2 (Drosophila Pc class); cell division cyc ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CBX2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCBX2
Namechromobox homolog 2
Aliases MGC10561; Pc class homolog (Drosophila); CDCA6; chromobox homolog 2 (Drosophila Pc class); cell division cyc ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CBX2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1160.809
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3550.786
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0530.962
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1930.737
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.1110.936
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2940.861
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5190.315
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0690.951
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.2520.271
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3110.539
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1230.856
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.6190.000631
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CBX2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCBX2
Namechromobox homolog 2
Aliases MGC10561; Pc class homolog (Drosophila); CDCA6; chromobox homolog 2 (Drosophila Pc class); cell division cyc ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CBX2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCBX2
Namechromobox homolog 2
Aliases MGC10561; Pc class homolog (Drosophila); CDCA6; chromobox homolog 2 (Drosophila Pc class); cell division cyc ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CBX2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CBX2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCBX2
Namechromobox homolog 2
Aliases MGC10561; Pc class homolog (Drosophila); CDCA6; chromobox homolog 2 (Drosophila Pc class); cell division cyc ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CBX2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCBX2
Namechromobox homolog 2
Aliases MGC10561; Pc class homolog (Drosophila); CDCA6; chromobox homolog 2 (Drosophila Pc class); cell division cyc ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CBX2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCBX2
Namechromobox homolog 2
Aliases MGC10561; Pc class homolog (Drosophila); CDCA6; chromobox homolog 2 (Drosophila Pc class); cell division cyc ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CBX2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCBX2
Namechromobox homolog 2
Aliases MGC10561; Pc class homolog (Drosophila); CDCA6; chromobox homolog 2 (Drosophila Pc class); cell division cyc ......
Chromosomal Location17q25.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CBX2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.